Shares of Jubilant Pharmova Limited dropped 2.41% to Rs 1,152.70 in early trade on Thursday, following news that the US Food and Drug Administration (USFDA) issued nine observations after inspecting its Jubilant HollisterStier General Partnership (JHSGP) facility in Montreal, Canada.
USFDA inspection details
According to a BSE filing, the audit of the JHSGP contract manufacturing facility concluded with nine observations. The company said that it will submit a detailed action plan to address these points.
JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited, which is a wholly owned subsidiary of Jubilant Pharmova.
About the company
Jubilant Pharmova (formerly Jubilant Life Sciences Limited) operates globally across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs segments.
Stock performance
As of 9:45 AM on November 6, the stock was trading at Rs 1,152.70, down Rs 28.50 from its previous close of Rs 1,181.20. The stock moved within a day range of Rs 1,155.00 to Rs 1,169.80, with a market capitalization of Rs 18,296 crore and a P/E ratio of 38.45.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
